Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04606446 · ClinicalTrials.gov registry record · Phase 1
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
A Phase 1 study of Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Locally Advanced or Metastatic ER+ HER2- Breast Cancer, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 320
- Enrollment target
- 20
- Study locations
NCT04606446 is a Phase 1 study of Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Locally Advanced or Metastatic ER+ HER2- Breast Cancer that is actively recruiting participants, run by Pfizer. The registered enrollment target is 320 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT04606446, a Phase 1 study of Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Locally Advanced or Metastatic ER+ HER2- Breast Cancer, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 320 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other agents
Conditions Studied
Interventions
- DRUG Letrozole
- DRUG Fulvestrant
- DRUG Palbociclib
- DRUG PF-07220060
- DRUG PF-07248144
Study Locations (20)
Tennessee
- Tennessee Oncology PLLC - Franklin
- Sarah Cannon Research Institute - Nashville
- Tennessee Oncology PLLC - Nashville
- The Sarah Cannon Research Institute / Tennessee Oncology, PLLC - Nashville
California
- Cedars Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute - Los Angeles
- Cedars-Sinai Medical Center; SOCCI Pharmacy - Los Angeles
- UCSF Medical Center at Mission Bay - San Francisco
Connecticut
- Smilow Cancer Hospital at Yale - New Haven - New Haven
- Yale-New Haven Hospital- Yale Cancer Center - New Haven
- Smilow Cancer Hospital Phase 1 Unit - New Haven
Kentucky
- St. Elizabeth Healthcare - Edgewood
- James Graham Brown Cancer Center - Louisville
- University Medical Center, lnc.:DBA University of Louisville Hospital - Louisville
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
- U.T. MD Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Washington
- Swedish Cancer Institute - Seattle
- Swedish Medical Center - Seattle
Arizona
- HonorHealth - Scottsdale
Florida
- Holy Cross Hospital - Fort Lauderdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2020-11-16 |
| Est. Completion | 2029-09-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04606446
The ClinicalTrials.gov registry entry for NCT04606446 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Locally Advanced or Metastatic Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Letrozole is the first listed.
NCT04606446 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Tennessee, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT04606446 about?
NCT04606446 is a clinical study titled "Study of PF-07248144 in Advanced or Metastatic Solid Tumors". This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other agents
What is the current status of trial NCT04606446?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 320 participants. The study started on 2020-11-16. Estimated completion is 2029-09-22.
What conditions does trial NCT04606446 study?
This clinical trial studies the following conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer.
What interventions are being tested in trial NCT04606446?
The interventions under investigation include: Letrozole (DRUG), Fulvestrant (DRUG), Palbociclib (DRUG), PF-07220060 (DRUG), PF-07248144 (DRUG).
Who is sponsoring clinical trial NCT04606446?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04606446 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
RECRUITING · Phase 1
-
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
All registered trials for this condition
Locally Advanced or Metastatic ER+ HER2- Breast Cancer
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.